ABAndrea Barbieri

Andrea Barbieri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andrea Barbieri has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Data from β-Galactosylceramidase Promotes Melanoma Growth via Modulation of Ceramide Metabolism

    by Mirella Belleri, Giuseppe Paganini, Daniela Coltrini, Roberto Ronca, Daniela Zizioli, Michela Corsini, Andrea Barbieri, Elisabetta Grillo, Stefano Calza, Roberto Bresciani, et al.

    Supplementary Data - Single file with supplemental methods, tables, figures, legends. Supplemental Materials and Methods; Table S1: Primers used for RT-qPCR analysis; Table S2: GALC downregulation affects the lipid profile of murine B16-F10 melanoma cells; Table S3: Expression levels of enzymes involved in sphingolipid metabolism in B16-F10 cells; Table S4: RT-qPCR analysis of the expression of tumor infiltrate markers and immune checkpoints in B16-F10 tumor grafts; Figure S1: Galca does not affect melanocyte differentiation in zebrafish; Figure S2: Galc downregulation does not affect cell cycle distribution and cell death in B16-F10 cells; Figure S3: The neutral sphingomyelinase inhibitor GW4869 increases the tumorigenic activity of shGALC-B16-F10 cells; Figure S4: Inhibition of the tumorigenic activity in shGALC-bis-B16-F10 cells; Figure S5: Public data mining of GALC expression in human melanoma; Figure S6: Public data mining of SMPD3 expression in human melanoma.

  • Open Access

    Supplementary Data from β-Galactosylceramidase Promotes Melanoma Growth via Modulation of Ceramide Metabolism

    by Mirella Belleri, Giuseppe Paganini, Daniela Coltrini, Roberto Ronca, Daniela Zizioli, Michela Corsini, Andrea Barbieri, Elisabetta Grillo, Stefano Calza, Roberto Bresciani, et al.

    Supplementary Data - Single file with supplemental methods, tables, figures, legends. Supplemental Materials and Methods; Table S1: Primers used for RT-qPCR analysis; Table S2: GALC downregulation affects the lipid profile of murine B16-F10 melanoma cells; Table S3: Expression levels of enzymes involved in sphingolipid metabolism in B16-F10 cells; Table S4: RT-qPCR analysis of the expression of tumor infiltrate markers and immune checkpoints in B16-F10 tumor grafts; Figure S1: Galca does not affect melanocyte differentiation in zebrafish; Figure S2: Galc downregulation does not affect cell cycle distribution and cell death in B16-F10 cells; Figure S3: The neutral sphingomyelinase inhibitor GW4869 increases the tumorigenic activity of shGALC-B16-F10 cells; Figure S4: Inhibition of the tumorigenic activity in shGALC-bis-B16-F10 cells; Figure S5: Public data mining of GALC expression in human melanoma; Figure S6: Public data mining of SMPD3 expression in human melanoma.

  • Open Access

    Data from β-Galactosylceramidase Promotes Melanoma Growth via Modulation of Ceramide Metabolism

    by Mirella Belleri, Giuseppe Paganini, Daniela Coltrini, Roberto Ronca, Daniela Zizioli, Michela Corsini, Andrea Barbieri, Elisabetta Grillo, Stefano Calza, Roberto Bresciani, et al.

    Disturbance of sphingolipid metabolism may represent a novel therapeutic target in metastatic melanoma, the most lethal form of skin cancer. β-Galactosylceramidase (GALC) removes β-galactose from galactosylceramide and other sphingolipids. In this study, we show that downregulation of galcb, a zebrafish ortholog of human GALC, affects melanoblast and melanocyte differentiation in zebrafish embryos, suggesting a possible role for GALC in melanoma. On this basis, the impact of GALC expression in murine B16-F10 and human A2058 melanoma cells was investigated following its silencing or upregulation. Galc knockdown hampered growth, motility, and invasive capacity of B16-F10 cells and their tumorigenic and metastatic activity when grafted in syngeneic mice or zebrafish embryos. Galc-silenced cells displayed altered sphingolipid metabolism and increased intracellular levels of ceramide, paralleled by a nonredundant upregulation of Smpd3, which encodes for the ceramide-generating enzyme neutral sphingomyelinase 2. Accordingly, GALC downregulation caused SMPD3 upregulation, increased ceramide levels, and inhibited the tumorigenic activity of human melanoma A2058 cells, whereas GALC upregulation exerted opposite effects. In concordance with information from melanoma database mining, RNAscope analysis demonstrated a progressive increase of GALC expression from common nevi to stage IV human melanoma samples that was paralleled by increases in microphthalmia transcription factor and tyrosinase immunoreactivity inversely related to SMPD3 and ceramide levels. Overall, these findings indicate that GALC may play an oncogenic role in melanoma by modulating the levels of intracellular ceramide, thus providing novel opportunities for melanoma therapy.Significance:Data from zebrafish embryos, murine and human cell melanoma lines, and patient-derived tumor specimens indicate that β-galactosylceramidase plays an oncogenic role in melanoma and may serve as a therapeutic target.

  • Open Access

    Data from β-Galactosylceramidase Promotes Melanoma Growth via Modulation of Ceramide Metabolism

    by Mirella Belleri, Giuseppe Paganini, Daniela Coltrini, Roberto Ronca, Daniela Zizioli, Michela Corsini, Andrea Barbieri, Elisabetta Grillo, Stefano Calza, Roberto Bresciani, et al.

    Disturbance of sphingolipid metabolism may represent a novel therapeutic target in metastatic melanoma, the most lethal form of skin cancer. β-Galactosylceramidase (GALC) removes β-galactose from galactosylceramide and other sphingolipids. In this study, we show that downregulation of galcb, a zebrafish ortholog of human GALC, affects melanoblast and melanocyte differentiation in zebrafish embryos, suggesting a possible role for GALC in melanoma. On this basis, the impact of GALC expression in murine B16-F10 and human A2058 melanoma cells was investigated following its silencing or upregulation. Galc knockdown hampered growth, motility, and invasive capacity of B16-F10 cells and their tumorigenic and metastatic activity when grafted in syngeneic mice or zebrafish embryos. Galc-silenced cells displayed altered sphingolipid metabolism and increased intracellular levels of ceramide, paralleled by a nonredundant upregulation of Smpd3, which encodes for the ceramide-generating enzyme neutral sphingomyelinase 2. Accordingly, GALC downregulation caused SMPD3 upregulation, increased ceramide levels, and inhibited the tumorigenic activity of human melanoma A2058 cells, whereas GALC upregulation exerted opposite effects. In concordance with information from melanoma database mining, RNAscope analysis demonstrated a progressive increase of GALC expression from common nevi to stage IV human melanoma samples that was paralleled by increases in microphthalmia transcription factor and tyrosinase immunoreactivity inversely related to SMPD3 and ceramide levels. Overall, these findings indicate that GALC may play an oncogenic role in melanoma by modulating the levels of intracellular ceramide, thus providing novel opportunities for melanoma therapy.Significance:Data from zebrafish embryos, murine and human cell melanoma lines, and patient-derived tumor specimens indicate that β-galactosylceramidase plays an oncogenic role in melanoma and may serve as a therapeutic target.

  • Open Access

    Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer

    by Davide Saronni, Germano Gaudenzi, Alessandra Dicitore, Silvia Carra, Maria Celeste Cantone, Maria Orietta Borghi, Andrea Barbieri, Luca Mignani, Leo J. Hofland, Luca Persani, et al.

    Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor arising from parafollicular C cells of the thyroid gland. In this preclinical study, we tested three tyrosine-kinase inhibitors (TKIs): SU5402, a selective inhibitor of fibroblast growth factor receptor (FGFR)-1 and vascular endothelial growth factor receptor (VEGFR)-2; sulfatinib, an inhibitor of FGFR-1 and VEGFR-1, -2, -3; and SPP86, a RET-specific inhibitor. The effects of these compounds were evaluated in vitro in two human MTC cell lines (TT and MZ-CRC-1), and in vivo using xenografts of MTC cells in zebrafish embryos. SU5402, sulfatinib and SPP86 decreased cell viability. Sulfatinib and SPP86 significantly induced apoptosis in both cell lines. Sulfatinib and SPP86 inhibited the migration of TT and MZCRC-1 cells, while SU5402 was able to inhibit migration only in TT cells. In vivo we observed a significant reduction in TT cell-induced angiogenesis in zebrafish embryos after incubation with sulfatinib and SPP86. In conclusion, sulfatinib and SPP86 displayed a relevant antitumor activity both in vitro and in vivo. Moreover, this work suggests the potential utility of targeting FGFR and VEGFR signaling pathways as an alternative therapy for MTC.


  • β-Galactosylceramidase Promotes Melanoma Growth via Modulation of Ceramide Metabolism

    by Mirella Belleri, Giuseppe Paganini, Daniela Coltrini, Roberto Ronca, Daniela Zizioli, Michela Corsini, Andrea Barbieri, Elisabetta Grillo, Stefano Calza, Roberto Bresciani, et al.

    Disturbance of sphingolipid metabolism may represent a novel therapeutic target in metastatic melanoma, the most lethal form of skin cancer. β-Galactosylceramidase (GALC) removes β-galactose from galactosylceramide and other sphingolipids. In this study, we show that downregulation of galcb, a zebrafish ortholog of human GALC, affects melanoblast and melanocyte differentiation in zebrafish embryos, suggesting a possible role for GALC in melanoma. On this basis, the impact of GALC expression in murine B16-F10 and human A2058 melanoma cells was investigated following its silencing or upregulation. Galc knockdown hampered growth, motility, and invasive capacity of B16-F10 cells and their tumorigenic and metastatic activity when grafted in syngeneic mice or zebrafish embryos. Galc-silenced cells displayed altered sphingolipid metabolism and increased intracellular levels of ceramide, paralleled by a nonredundant upregulation of Smpd3, which encodes for the ceramide-generating enzyme neutral sphingomyelinase 2. Accordingly, GALC downregulation caused SMPD3 upregulation, increased ceramide levels, and inhibited the tumorigenic activity of human melanoma A2058 cells, whereas GALC upregulation exerted opposite effects. In concordance with information from melanoma database mining, RNAscope analysis demonstrated a progressive increase of GALC expression from common nevi to stage IV human melanoma samples that was paralleled by increases in microphthalmia transcription factor and tyrosinase immunoreactivity inversely related to SMPD3 and ceramide levels. Overall, these findings indicate that GALC may play an oncogenic role in melanoma by modulating the levels of intracellular ceramide, thus providing novel opportunities for melanoma therapy. Significance: Data from zebrafish embryos, murine and human cell melanoma lines, and patient-derived tumor specimens indicate that β-galactosylceramidase plays an oncogenic role in melanoma and may serve as a therapeutic target.


  • Open Access

    Atypical Chemokine Receptor 3 Generates Guidance Cues for CXCL12-Mediated Endothelial Cell Migration

    by Chiara Tobia, Paola Chiodelli, Andrea Barbieri, Simone Buraschi, Elena Ferrari, Stefania Mitola, Giuseppe Borsani, Jessica Guerra, Marco Presta

    Chemokine receptor CXCR4, its ligand stromal cell-derived factor-1 (CXCL12) and the decoy receptor atypical chemokine receptor 3 (ACKR3, also named CXCR7), are involved in the guidance of migrating cells in different anatomical districts. Here, we investigated the role of the ACKR3 zebrafish ortholog ackr3b in the vascularization process during embryonic development. Bioinformatics and functional analyses confirmed that ackr3b is a CXCL12-binding ortholog of human ACKR3. ackr3b is transcribed in the endoderm of zebrafish embryos during epiboly and is expressed in a wide range of tissues during somitogenesis, including central nervous system and somites. Between 18 somite and 26 h-post fertilization stages, the broad somitic expression of ackr3b becomes restricted to the basal part of the somites. After ackr3b knockdown, intersomitic vessels (ISVs) lose the correct direction of migration and are characterized by the presence of aberrant sprouts and ectopic filopodia protrusions, showing downregulation of the tip/stalk cell marker hlx1. In addition, ackr3b morphants show significant alterations of lateral dorsal aortae formation. In keeping with a role for ackr3b in endothelial cell guidance, CXCL12 gradient generated by ACKR3 expression in CHO cell transfectants guides human endothelial cell migration in an in vitro cell co-culture chemotaxis assay. Our results demonstrate that ackr3b plays a non-redundant role in the guidance of sprouting endothelial cells during vascular development in zebrafish. Moreover, ACKR3 scavenging activity generates guidance cues for the directional migration of CXCR4-expressing human endothelial cells in response to CXCL12.


  • Sel1l knockdown negatively influences zebrafish embryos endothelium

    by Andrea Barbieri, Silvia Carra, Pasquale De Blasio, Franco Cotelli, Ida Biunno

    SEL1L (suppressor/enhancer of Lin‐12‐like) is a highly conserved gene associated with the endoplasmic reticulum‐associated degradation (ERAD) pathway and involved in mediating the balance between stem cells self‐renewal and differentiation of neural progenitors. It has been recently shown that SEL1L KO mice are embryonic lethal and display altered organogenesis. To better characterize the function of SEL1L in the early stages of embryonic development, we turned to the zebrafish model (Danio rerio). After exploring sel1l expression by RT‐PCR and in situ hybridization, we employed a morpholino‐mediated down‐regulation approach. Results showed extensive impairments in the vasculature, which supports the mice knock‐out findings.


  • Strategies to obtain multiple recombinant modified vaccinia Ankara vectors. Applications to influenza vaccines

    by Andrea Barbieri, Maddalena Panigada, Elisa Soprana, Giuseppina Di Mario, Francesco Gubinelli, Valentina Bernasconi, Marta Recagni, Isabella Donatelli, Maria R. Castrucci, Antonio G. Siccardi


  • mSEL‐1L deficiency affects vasculogenesis and neural stem cell lineage commitment

    by Marina Cardano, Giuseppe R. Diaferia, Luciano Conti, Simona Baronchelli, Alessandro Sessa, Vania Broccoli, Andrea Barbieri, Pasquale De Blasio, Ida Biunno

    MSEL‐1L is a highly conserved ER‐resident type I protein, involved in the degradation of misfolded peptides through the ubiquitin–proteasome system (UPS), a pathway known to control the plasticity of the vascular smooth muscle cells (VSMC) phenotype and survival. In this article, we demonstrate that mSEL‐1L deficiency interferes with the murine embryonic vascular network, showing particular irregularities in the intracranic and intersomitic neurovascular units and in the cerebral capillary microcirculation. During murine embryogenesis, mSEL‐1L is expressed in cerebral areas known to harbor progenitor neural cells, while in the adult brain the protein is specifically restricted to the stem cell niches, co‐localizing with Sox2 and Nestin. Null mice are characterized by important defects in the development of telenchephalic regions, revealing conspicuous aberration in neural stem cell lineage commitment. Moreover, mSEL‐1L depletion in vitro and in vivo appears to affect the harmonic differentiation of the NSCs, by negatively influencing the corticogenesis processes. Overall, the data presented suggests that the drastic phenotypic characteristics exhibited in mSEL‐1L null mice can, in part, be explained by the negative influence it plays on Notch1 signaling pathway.